275 related articles for article (PubMed ID: 30003668)
1. Exploring the flap dynamics of the South African HIV subtype C protease in presence of FDA-approved inhibitors: MD study.
Maphumulo SI; Halder AK; Govender T; Maseko S; Maguire GEM; Honarparvar B; Kruger HG
Chem Biol Drug Des; 2018 Nov; 92(5):1899-1913. PubMed ID: 30003668
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the molecular dynamics and calculated binding free energies for nine FDA-approved HIV-1 PR drugs against subtype B and C-SA HIV PR.
Ahmed SM; Kruger HG; Govender T; Maguire GE; Sayed Y; Ibrahim MA; Naicker P; Soliman ME
Chem Biol Drug Des; 2013 Feb; 81(2):208-18. PubMed ID: 23017010
[TBL] [Abstract][Full Text] [Related]
3. Structural and binding insights into HIV-1 protease and P2-ligand interactions through molecular dynamics simulations, binding free energy and principal component analysis.
Karnati KR; Wang Y
J Mol Graph Model; 2019 Nov; 92():112-122. PubMed ID: 31351319
[TBL] [Abstract][Full Text] [Related]
4. I36T↑T mutation in South African subtype C (C-SA) HIV-1 protease significantly alters protease-drug interactions.
Maseko SB; Padayachee E; Govender T; Sayed Y; Kruger G; Maguire GEM; Lin J
Biol Chem; 2017 Sep; 398(10):1109-1117. PubMed ID: 28525359
[TBL] [Abstract][Full Text] [Related]
5. Structural insights into the South African HIV-1 subtype C protease: impact of hinge region dynamics and flap flexibility in drug resistance.
Naicker P; Achilonu I; Fanucchi S; Fernandes M; Ibrahim MA; Dirr HW; Soliman ME; Sayed Y
J Biomol Struct Dyn; 2013 Dec; 31(12):1370-80. PubMed ID: 23140382
[TBL] [Abstract][Full Text] [Related]
6. Interaction of I50V mutant and I50L/A71V double mutant HIV-protease with inhibitor TMC114 (darunavir): molecular dynamics simulation and binding free energy studies.
Meher BR; Wang Y
J Phys Chem B; 2012 Feb; 116(6):1884-900. PubMed ID: 22239286
[TBL] [Abstract][Full Text] [Related]
7. Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease.
Gupta A; Jamal S; Goyal S; Jain R; Wahi D; Grover A
BMC Bioinformatics; 2015; 16 Suppl 19(Suppl 19):S10. PubMed ID: 26695135
[TBL] [Abstract][Full Text] [Related]
8. Investigation of the binding free energies of FDA approved drugs against subtype B and C-SA HIV PR: ONIOM approach.
Sanusi ZK; Govender T; Maguire GEM; Maseko SB; Lin J; Kruger HG; Honarparvar B
J Mol Graph Model; 2017 Sep; 76():77-85. PubMed ID: 28711760
[TBL] [Abstract][Full Text] [Related]
9. A contribution to the drug resistance mechanism of darunavir, amprenavir, indinavir, and saquinavir complexes with HIV-1 protease due to flap mutation I50V: a systematic MM-PBSA and thermodynamic integration study.
Leonis G; Steinbrecher T; Papadopoulos MG
J Chem Inf Model; 2013 Aug; 53(8):2141-53. PubMed ID: 23834142
[TBL] [Abstract][Full Text] [Related]
10. Importance of polar solvation and configurational entropy for design of antiretroviral drugs targeting HIV-1 protease.
Kar P; Lipowsky R; Knecht V
J Phys Chem B; 2013 May; 117(19):5793-805. PubMed ID: 23614718
[TBL] [Abstract][Full Text] [Related]
11. Could the FDA-approved anti-HIV PR inhibitors be promising anticancer agents? An answer from enhanced docking approach and molecular dynamics analyses.
Arodola OA; Soliman ME
Drug Des Devel Ther; 2015; 9():6055-65. PubMed ID: 26622167
[TBL] [Abstract][Full Text] [Related]
12. An insight to the molecular interactions of the FDA approved HIV PR drugs against L38L↑N↑L PR mutant.
Sanusi ZK; Govender T; Maguire GEM; Maseko SB; Lin J; Kruger HG; Honarparvar B
J Comput Aided Mol Des; 2018 Mar; 32(3):459-471. PubMed ID: 29397520
[TBL] [Abstract][Full Text] [Related]
13. Exploring the drug resistance of V32I and M46L mutant HIV-1 protease to inhibitor TMC114: flap dynamics and binding mechanism.
Meher BR; Wang Y
J Mol Graph Model; 2015 Mar; 56():60-73. PubMed ID: 25562662
[TBL] [Abstract][Full Text] [Related]
14. Computational studies of darunavir into HIV-1 protease and DMPC bilayer: necessary conditions for effective binding and the role of the flaps.
Leonis G; Czyżnikowska Ż; Megariotis G; Reis H; Papadopoulos MG
J Chem Inf Model; 2012 Jun; 52(6):1542-58. PubMed ID: 22587384
[TBL] [Abstract][Full Text] [Related]
15. The impact of active site mutations of South African HIV PR on drug resistance: Insight from molecular dynamics simulations, binding free energy and per-residue footprints.
Ahmed SM; Maguire GE; Kruger HG; Govender T
Chem Biol Drug Des; 2014 Apr; 83(4):472-81. PubMed ID: 24267738
[TBL] [Abstract][Full Text] [Related]
16. Interchain hydrophobic clustering promotes rigidity in HIV-1 protease flap dynamics: new insights from molecular dynamics.
Meher BR; Kumar MV; Bandyopadhyay P
J Biomol Struct Dyn; 2014; 32(6):899-915. PubMed ID: 23782135
[TBL] [Abstract][Full Text] [Related]
17. Amide hydrogen exchange in HIV-1 subtype B and C proteases--insights into reduced drug susceptibility and dimer stability.
Naicker P; Stoychev S; Dirr HW; Sayed Y
FEBS J; 2014 Dec; 281(24):5395-410. PubMed ID: 25283307
[TBL] [Abstract][Full Text] [Related]
18. Unraveling HIV protease flaps dynamics by Constant pH Molecular Dynamics simulations.
Soares RO; Torres PHM; da Silva ML; Pascutti PG
J Struct Biol; 2016 Aug; 195(2):216-226. PubMed ID: 27291071
[TBL] [Abstract][Full Text] [Related]
19. Effects of drug-resistant mutations on the dynamic properties of HIV-1 protease and inhibition by Amprenavir and Darunavir.
Yu Y; Wang J; Shao Q; Shi J; Zhu W
Sci Rep; 2015 May; 5():10517. PubMed ID: 26012849
[TBL] [Abstract][Full Text] [Related]
20. Exploring the energetic basis of binding of currently used drugs against HIV-1 subtype CRF01_AE protease via molecular dynamics simulations.
Sk MF; Jonniya NA; Kar P
J Biomol Struct Dyn; 2021 Oct; 39(16):5892-5909. PubMed ID: 32696717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
